I'll research this company to verify its profile.
Let me verify the litigation context and corporate lineage.
GenPharm International, Inc. was a U.S. biotechnology company founded in 1989 and headquartered in Palo Alto / San Jose, California. It was a privately held, venture-backed company (investors included Abingworth, Atlas Venture, Avalon Ventures and Collagen Corporation) that had attempted a public offering but shelved it amid litigation. It is not related to the similarly named Genpharm Services (a Dubai-based rare-disease market-access firm) or Genpharm Inc. (Canada).
Products / operations. GenPharm developed transgenic-animal technology for producing fully human monoclonal antibodies. Its core platform was the HuMAb-Mouse, a mouse strain engineered with human immunoglobulin genes to generate high-affinity, fully human antibodies for therapeutic use. GenPharm did not market drugs; its business was technology licensing and antibody-discovery collaborations. It signed a reported ~$57 million licensing deal with Centocor for HuMAb-Mouse technology, and also held patents (licensed to third parties such as Lexicon Genetics) covering gene-targeting/"knockout" methods.
Corporate history. Medarex, Inc. (NASDAQ: MEDX) acquired GenPharm in October 1997 for up to approximately $62–65 million in Medarex stock. GenPharm thereafter operated as a wholly owned Medarex subsidiary and continued to be named as a contracting party in Medarex licensing agreements. Bristol-Myers Squibb acquired Medarex for $2.4 billion in 2009, making GenPharm a BMS subsidiary; its antibody technology underlies products including Stelara (ustekinumab).
Patent-litigation posture. The case data reflects an operating biotech company engaged in two-way IP litigation over its core platform — one suit as plaintiff, one as defendant — not an NPE asserting an acquired portfolio. GenPharm sued Abgenix, Inc. (plaintiff) after receiving U.S. Patents 5,545,806 and 5,569,825 on transgenic human-antibody mice. In the mirror-image case, Cell Genesys, Inc. sued GenPharm (defendant) in 1994, alleging theft of trade secrets related to mouse antibody-gene inactivation.
Notable context. Both suits were resolved in March 1997 by a comprehensive cross-license among GenPharm, Cell Genesys, Abgenix, Xenotech L.P. and Japan Tobacco, under which Cell Genesys/Japan Tobacco paid GenPharm up to ~$30 million. That settlement cleared the way for the Medarex acquisition later that year. The tracked cases ceased after the 1997 settlement.